文献速递乳腺乳腺X线

人工智能在乳腺癌乳腺X线筛查中应用效果的早期指标

Early Indicators of the Impact of Using AI in Mammography Screening for Breast Cancer.
PubMed 文献 · Radiology · 2024-01-01

该回顾性研究纳入丹麦首都地区50-69岁接受两年一次乳腺X线筛查的女性,比较AI系统实施前后(实施前60751例、实施后58246例)的工作负荷与筛查性能。AI实施后召回率下降20.5%、癌症检出率升高、假阳性率下降、阳性预测值升高、小癌(≤1 cm)比例升高、浸润性癌比例下降,阅片工作负荷降低33.5%。

要点

  • AI实施后召回率由3.09%降至2.46%,假阳性率由2.39%降至1.63%。
  • 癌症检出率由0.70%升至0.82%,阳性预测值由22.6%升至33.6%。
  • 小癌(≤1 cm)比例由36.6%升至44.9%,阅片工作负荷降低33.5%。

核心结论

  • 在基于人群的乳腺X线筛查项目中,使用AI降低了乳腺放射科医生的总体工作负荷,同时改善了筛查性能。

研究设计与样本

  • 回顾性研究,纳入丹麦首都地区50-69岁接受两年一次乳腺X线筛查的女性,AI实施前60751例、实施后58246例,两队列中位年龄均为58岁(IQR 54-64岁)。

诊断标准与关键数值

  • AI实施后,可能正常的筛查(2022年5月3日前AI检查评分≤5,2022年5月3日及之后≤7)由19名资深全职乳腺放射科医生中的一名进行单读,其余筛查由两名放射科医生借助AI辅助决策支持判读;活检与手术结局检索时间为2020年10月1日至2023年4月15日,确保至少180天随访。

临床应用与阅片要点

  • AI实施后召回率下降20.5%(实施前3.09%[1875/60751] vs 实施后2.46%[1430/58246],P < .001),癌症检出率升高(0.70%[423/60751] vs 0.82%[480/58246],P = .01),假阳性率下降(2.39%[1452/60751] vs 1.63%[950/58246],P < .001),阳性预测值升高(22.6%[423/1875] vs 33.6%[480/1430],P < .001),小癌(≤1 cm)比例升高(36.6%[127/347] vs 44.9%[164/365],P = .02),淋巴结阴性癌比例无变化(76.7%[253/330] vs 77.8%[273/351],P = .73),浸润性癌比例下降(84.9%[359/423] vs 79.6%[382/480],P = .04),阅片工作负荷降低33.5%(38977/116492次阅片)。

局限性

  • AI实施前中位筛查间隔为845天(IQR 820-878天),AI实施后为993天(IQR 968-1013天),P < .001。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Retrospective studies have suggested that using artificial intelligence (AI) may decrease the workload of radiologists while preserving mammography screening performance. Purpose To compare workload and screening performance for two cohorts of women who underwent screening before and after AI system implementation. Materials and Methods This retrospective study included 50-69-year-old women who underwent biennial mammography screening in the Capital Region of Denmark. Before AI system implementation (October 1, 2020, to November 17, 2021), all screenings involved double reading. For screenings conducted after AI system implementation (November 18, 2021, to October 17, 2022), likely normal screenings (AI examination score ≤5 before May 3, 2022, or ≤7 on or after May 3, 2022) were single read by one of 19 senior full-time breast radiologists. The remaining screenings were read by two radiologists with AI-assisted decision support. Biopsy and surgical outcomes were retrieved between October 1, 2020, and April 15, 2023, ensuring at least 180 days of follow-up. Screening metrics were compared using the χ2 test. Reading workload reduction was measured as saved screening reads. Results In total, 60 751 and 58 246 women were screened before and after AI system implementation, respectively (median age, 58 years [IQR, 54-64 years] for both cohorts), with a median screening interval before AI of 845 days (IQR, 820-878 days) and with AI of 993 days (IQR, 968-1013 days; P < .001). After AI system implementation, the recall rate decreased by 20.5% (3.09% before AI [1875 of 60 751] vs 2.46% with AI [1430 of 58 246]; P < .001), the cancer detection rate increased (0.70% [423 of 60 751] vs 0.82% [480 of 58 246]; P = .01), the false-positive rate decreased (2.39% [1452 of 60 751] vs 1.63% [950 of 58 246]; P < .001), the positive predictive value increased (22.6% [423 of 1875] vs 33.6% [480 of 1430]; P < .001), the rate of small cancers (≤1 cm) increased (36.6% [127 of 347] vs 44.9% [164 of 365]; P = .02), the rate of node-negative cancers was unchanged (76.7% [253 of 330] vs 77.8% [273 of 351]; P = .73), and the rate of invasive cancers decreased (84.9% [359 of 423] vs 79.6% [382 of 480]; P = .04). The reading workload was reduced by 33.5% (38 977 of 116 492 reads). Conclusion In a population-based mammography screening program, using AI reduced the overall workload of breast radiologists while improving screening performance. Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Lee and Friedewald in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lauritzen AD, Lillholm M, Lynge E, et al. Early Indicators of the Impact of Using AI in Mammography Screening for Breast Cancer. Radiology. 2024. PMID: 38832880. doi:10.1148/radiol.232479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。